Chase Doyle
Authored Items
In April 2017, midostaurin (Rydapt) was approved for the treatment of adults with newly diagnosed FLT3-positive AML in combination with standard intensive induction consolidation chemotherapy.
Read Bio ›“The main rationale from the cytotoxic era is to increase efficacy by combining agents that have different mechanisms and nonoverlapping toxicities. The question is whether we can replace nonspecific cytotoxic agents with a specific, more effective immunotherapeutic,” said Donna Przepiorka, MD, PhD, at ASH 2017.
Read Bio ›San Francisco, CA—Many patients with advanced melanoma or advanced lung cancer have benefited from treatment with checkpoint inhibitors, which have helped extend survival to previously unthinkable lengths. Although the impression is that checkpoint inhibitors are free of adverse events, in reality, clinicians strive daily to balance the efficacy and toxicity of these treatments.
Read Bio ›